Managed entry agreements for pharmaceuticals in Australia

Health Policy

Volumn 117, Issue 3, 2014, Pages 345-352

  Vitry, Agnes ^a   Roughead, Elizabeth ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Coverage with evidence development; Managed entry agreement; Medicine subsidization; Pharmaceutical policy

Indexed keywords

BOSENTAN; DRUG; PRESCRIPTION DRUG;

ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; FUNDING; GOVERNMENT; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; MANAGED ENTRY AGREEMENT; PULMONARY HYPERTENSION; ECONOMICS; HEALTH INSURANCE; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PHARMACOECONOMICS; REIMBURSEMENT;

AUSTRALIA; DECISION MAKING, ORGANIZATIONAL; ECONOMICS, PHARMACEUTICAL; MANAGED CARE PROGRAMS; PHARMACEUTICAL PREPARATIONS; PRESCRIPTION DRUGS; REIMBURSEMENT MECHANISMS;

EID: 84908211150     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2014.05.005     Document Type: Article

References (37)

1. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013, 121:4439-4442. Experts in Chronic Myeloid Leukemia.
2. O'Sullivan B.P., Orenstein D.M., Milla C.E. Pricing for orphan drugs will the market bear what society cannot. Journal of American Medical Association 2013, 310:1343-1344.
3. ® - July 2013, http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-07/ivacaftor [28.04.14].
4. ® - November 2013, http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-11/ivacaftor [28.04.14].
5. Australian Government, Department of Health and Ageing Annual report 2012-2013 2013, http://www.health.gov.au/internet/main/publishing.nsf/Content/annual-report2012-13 [18.12.13].
6. Australian National Audit Office, Commonwealth of Australia Selected measures for managing subsidised drug use in the Pharmaceutical Benefits Scheme. Audit Report no. 44 2005-06 Performance Audit 2012, http://www.anao.gov.au/uploads/documents/2005-06_Audit_Report_44.pdf [17.04.12].
7. Klemp M., Frønsdal K.B., Facey K. What principles should govern the use of managed entry agreements. International Journal of Technology Assessment in Health Care 2011, 27:77-83.
8. PBS Information Management Section, Pharmaceutical Policy Branch, Department of Health and Ageing Expenditure and prescriptions twelve months to June 2012, http://www.pbs.gov.au/statistics/2011-2012-files/expenditure-and-prescriptions-2011-2012.pdf [03.01.14].
9. The Hon Peter Dutton MP, Minister for Health, Minister for Sport.Media Release Australians to access more affordable medicines sooner 2013, http://www.health.gov.au/internet/ministers/publishing.nsf/Content/4084C89B3E2171EBCA257C140001CA8C/$File/PD007.pdf [18.12.13].
10. Australian Government, Department of Health Memorandum of understanding between the Commonwealth of Australia and Medicines Australia 2013, http://www.health.gov.au/internet/main/publishing.nsf/Content/further-PBS-reforms-Agreement [14.06.13].
11. Australian Government, Department of Health Framework for the introduction of a Managed Entry Scheme for submissions to the Pharmaceutical Benefits Advisory Committee 2013, http://www.pbs.gov.au/info/publication/factsheets/shared/framework-for-introduction-of-managed-entry-scheme-for-PBAC-submissions [14.06.13].
12. Carlson J.J., Sullivan S.D., Garrison L.P., Neumann P.J., Veenstra D.L. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy 2010, 96:179-190.
13. Adamski J., Godman B., Ofierska-Sujkowska G., Osinska B., Herholz H., Wendykowska K., et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Research 2010, 10:153.
14. Ferrario A., Kanavos P. Managed entry agreements for pharmaceuticals: the European experience 2013, http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/mea_report_en.pdf [27.11.13].
15. HTAi Health Technology Assessment International (HTAi) interest subgroup - conditional coverage/access with evidence development 2013, http://www.htai.org/ [14.06.13].
16. Australian Government, Department of Health Schedule of Pharmaceutical Benefits February 2013, http://www.pbs.gov.au/browse/publications [14.06.13].
17. Australian Government, Department of Health, Pharmaceutical Benefits Pricing Authority (PBPA) Therapeutic relativity sheets - 1 October 2012, http://www.pbs.gov.au/info/industry/pricing/pbs-items/therapeutic-relativity-sheets [14.06.13].
18. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD index 2014, http://www.whocc.no/atc_ddd_index/ [28.04.14].
19. Pharmaceutical Benefit Advisory Committee PBAC outcomes and public summary documents 2013, http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-outcomes-and-public-summary-documents [14.06.13].
20. Australian Government, Department of Health, Pharmaceutical Benefits Pricing Authority (PBPA) PBPA Policies, Procedures and Methods. Pricing of new products proposed for listing on the Pharmaceutical Benefits Scheme (PBS) 2013, http://www.health.gov.au/internet/publications/publishing.nsf/Content/pbs-pbpa-policies-contents~pbs-pbpa-policies-ch3 [14.06.13].
21. Australian Government, Department of Health Guidelines for deeds of agreement for the Pharmaceutical Benefits Scheme. Version 1.3 2013, http://www.pbs.gov.au/industry/listing/elements/deeds-agreement/Guidelines_for_Deeds_of_Agreement.pdf [14.06.13].
22. Wlodarczyk J., Reid C.M., Pater G. Funding linked to ongoing research: impact of the Bosentan Patient Registry on Pricing in Australia. Value Health 2011, 14:961-963.
23. Keogh A., Strange G., McNeil K., Williams T.J., Gabbay E., Proudman S., et al. The bosentan patient registry: long-term survival in pulmonary arterial hypertension. Internal Medicine Journal 2011, 41:227-234.
24. ®, July 2010, http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-Pazopanib-july10 [18.12.13].
25. Pharmaceutical Benefits Advisory Committee November 2012 PBAC Outcomes - Positive Recommendations 2013, http://www.health.gov.au/internet/main/publishing.nsf/content/health-pbs-general-listing-committee3.htm [14.06.13].
26. Pharmaceutical Benefits Advisory Committee Avril 2013 PBAC Outcomes - Positive Recommendations 2013, http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/2013-04/positive-recommendations [24.07.13].
27. Australian Government, Department of Health and Ageing Annual Report 2011-2012. Appendix 2: Pharmaceutical Benefits Pricing Authority Annual Report for the year ended 30 June 2012, http://www.health.gov.au/internet/annrpt/publishing.nsf/Content/annual-report-1112-toc~11-12append~11-12app2 [14.06.13].
28. Robertson J., Walkom E.J., Henry D.A. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. Australian Health Review 2009, 33:192-199.
29. Pharmaceutical Benefit Advisory Committee PBAC Review of bDMARDs for the treatment of severe active rheumatoid arthritis 2013, http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-bdmards-dec09 [14.06.13].
30. Pharmaceutical Benefit Advisory Committee PBAC Recommendations from the Review of Pharmaceutical Benefits Scheme Anti-dementia Drugs to Treat Alzheimer Disease 2013, http://www.pbs.gov.au/info/reviews/pbac-minutes-alzheimers [14.06.13].
31. Tunis S.R., Pearson S.D. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Affairs 2006, 25:1218-1230.
32. Menon D., McCabe C.J., Stafinski T., Edlin R. Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit. Pharmacoeconomics 2010, 28:109-111.
33. Trueman P., Grainger D.L., Downs K.E. Coverage with evidence development: applications and issues. International Journal of Technology Assessment in Health Care 2010, 26:79-85.
34. Cheema P.K., Gavura S., Migus M., Godman B., Yeung L., Trudeau M.E. International variability in the reimbursement of cancer drugs by publically funded drug programs. Current Oncology 2012, 19:e165-e176.
35. Morgan S., Daw J., Thomson P. International best practices for negotiating 'reimbursement contracts' with price rebates from pharmaceutical companies. Health Affairs (Millwood) 2013, 32:771-777.
36. Robertson J., Walkom E.J., Bevan M.D., Newby D.A. Medicines and the media: news reports of medicines recommended for government reimbursement in Australia. BMC Public Health 2013, 13:489.
37. Lopert R., Elshaug A.G. Australia's 'Fourth Hurdle' Drug Review Comparing Costs And Benefits Holds Lessons For The United States. Health Affairs (Project Hope) 2013, 32:778-787.